Radiopharmaceutical needed for prostate cancer patient with metastatic lesions after definite treatment sofie (S0F-neuraceq)
Ended Awarded
- Contract number
- HT009025FG081100
- Awardee
-
Sofie CO. UEI JV1AHJHGUGG3
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $43,658
Award facts
- Contract value 100% obligated
- $43,658.48 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6506 Blood And Blood Products
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Sterling, VA, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency awarded Sofie CO., doing business as IBA Molecular, a $43,658.48 firm fixed-price task order under an existing blanket purchase agreement for the supply of Sofie (Sodium Fluoride-18 FAPI), a radiopharmaceutical used in positron emission tomography imaging for prostate cancer patients with metastatic lesions who have completed definitive treatment. The contract was awarded on July 23, 2025, with a completion date of September 30, 2025, and will be performed at the contractor's facility in Sterling, Virginia. This award was made without set-aside designations, reflecting the specialized and competitive nature of the radiopharmaceutical market.
Sofie CO. is a for-profit subsidiary of Sofie Biosciences specializing in the development and distribution of molecular diagnostics and therapeutic radiopharmaceuticals to federal healthcare agencies. The Defense Health Agency maintains multiple blanket purchase agreements with the contractor for radiopharmaceutical supplies, which facilitate task order issuance for specialized PET imaging agents across military treatment facilities. This particular task order supports the ongoing medical imaging needs of military personnel and demonstrates the Defense Health Agency's reliance on Sofie CO.'s specialized radiopharmaceutical products for diagnostic oncology procedures within the military healthcare system.
Quick answers
Who was awarded contract HT009025FG081100?
HT009025FG081100 was awarded to Sofie CO. by Defense Health Agency (Department of Defense) on July 23, 2025.
How much is contract HT009025FG081100 worth?
The government has obligated $43,658 on HT009025FG081100.
Is contract HT009025FG081100 an order under another contract?
Yes. HT009025FG081100 is a BPA call under HT001424A0002, a blanket purchase agreement.
Was contract HT009025FG081100 competed?
The extent of competition for HT009025FG081100 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award